Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-cancer therapeutics - AstraZeneca

Next Previous
Drug Profile

Research programme: anti-cancer therapeutics - AstraZeneca

Alternative Names: MEDI 1109; MEDI 3387; MEDI 5771; OX40/PD-L1 bispecific antibodies - AstraZeneca ; PD-1/GITRL bispecific fusion proteins - AstraZeneca

Latest Information Update: 28 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; OX40 receptor agonists; Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors; TNFRSF18 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 May 2022 No recent reports of development identified for preclinical development in Cancer in USA (IV)
  • 21 Apr 2018 Preclinical trials in Cancer in USA (IV) before April 2018 (3317744; 3318386)
  • 21 Apr 2018 Pharmacodynamics and immunogenicity data from preclinical studies in Cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018) (3317744; 3318386)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top